No Data
No Data
HK stocks fluctuation: Hutchmed (China) (00013) rises by more than 9% again, the company recently shared the latest pipeline progress, institutions stated that there are multiple catalysts in the second half of the year.
Hutchmed (China) (00013) rose more than 9%, as of press time, it rose 7.03% to HKD 29.7, with a turnover of HKD 0.114 billion.
Bocom Intl maintains a buy rating for Hutchmed (China) (00013) with a target price of HK$40.
According to the report released by Bocom International on the Zhongtong Finance and Economics App, they maintain buy rating for Hutchmed (China) (00013) with a target price of HKD 40. The report stated that the catalysts for the second half of 2024 include global sales of Fruquintinib and domestic approval progress based on Frutiga research for 2L gastric cancer as well as global declaration based on SAVANNAH research for Savolitinib. The domestic approval for Surufatinib was also mentioned. The bank pointed out that the effectiveness of the combination therapy of Sulfatinib and PD-1 for pancreatic cancer treatment is encouraging. One IIT data announced at ASCO GI conference showed that the combination of Sulfatinib and AS therapy is
BofA Securities Maintains Hutchmed (China)(HCM.US) With Buy Rating, Maintains Target Price $29
BofA Securities analyst Alec Stranahan maintains $Hutchmed (China)(HCM.US)$ with a buy rating, and maintains the target price at $29.According to TipRanks data, the analyst has a success rate of 46.2%
HUTCHMED: A Strong Buy on Global Expansion and Pipeline Potential
Guoyuan Securities: Each overseas business model has its own advantages and disadvantages. Pharmaceutical companies should choose according to their own size.
Leveraging external resources is currently the most mainstream mode for Chinese pharmaceutical companies to expand overseas, which is suitable for companies with limited resources and in need of international experience accumulation, but it also means that the company's voice will be weakened and the relative benefits of sharing will be limited.
Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating
Goldman Sachs analyst Paul Choi maintains $Hutchmed (China)(HCM.US)$ with a hold rating.According to TipRanks data, the analyst has a success rate of 51.3% and a total average return of 7.1% over
No Data
DailyHunt : Do you think is ready?
Momentum TraderOP DailyHunt: Already Bo from pivot. Don’t chase high!